Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

14.38 UNCHANGED
Official Closing Price Updated: 7:00 PM EST, Mar 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
The Last Day In January ↗
The market is suspicious of the moves up to right matters. 
Via Talk Markets
News headline image
Earnings Scheduled For January 28, 2022 ↗
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its third quarter. • LyondellBasell Industries (NYSE:... 
Via Benzinga
News headline image
Reddy's To Launch Generic Version Of Merck's COVID-19 Drug At $0.50/Pill: Reuters ↗
India-based Dr Reddy's Laboratories Ltd (NYSE: RDY) will launch its generic version of Merck Co & Inc's (NYSE: MRK) COVID-19 antiviral pill, ... 
Via Benzinga
News headline image
Happy New Year - Sunday Edition ↗
Starting a new year - we look at tech, pharma and mining stocks and their goings-on. 
Via Talk Markets
News headline image
Market Trend: Erratic And Unreliable ↗
Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is. 
Via Talk Markets
News headline image
A Bit Of Good News ↗
US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%. 
Via Talk Markets
News headline image
Dr. Reddy's Laboratories Announces the Launch of Venlafaxine ER Tablets in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Valsartan Tablets, USP in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Prestige BioPharma and Dr. Reddy’s announce partnership to commercialize trastuzumab biosimilar in select countries in Latin America and Southeast Asia
From Prestige BioPharma Ltd.
Via Business Wire
News headline image
5 Reasons Why Sensex Crashed, Tarsons Products' Lukewarm Debut, And Buzzing Stocks Today ↗
Indian share markets, which ended deep in the red on Friday, are headed for a gap-up opening today following the trend on SGX Nifty. 
Via Talk Markets
News headline image
Tuesday Market Overview ↗
While gold gained modestly again today, cryptocurrencies fell hard. 
Via Talk Markets
News headline image
Dr. Reddy's Ready To Make COVID-19 Antiviral From Pfizer - Reuters ↗
Dr. Reddy's Laboratories Ltd (NYSE: RDY) said it was open to making Pfizer Inc's (NYSE: PFE) COVID-19 antiviral pill, Reuters reported. The new drugs can... 
Via Benzinga
News headline image
Dr. Reddy's Laboratories Announces the Launch of Ephedrine Sulfate Injection USP, 50 mg/mL, Single-Dose Vial in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Wednesday Market Coverage ↗
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
News headline image
Bitcoin Futures Arrive ↗
Today you can finally hold Bitcoins via an exchange-traded fund. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... 
Via Benzinga
News headline image
Dr. Reddy's Laboratories Announces Approval for Lenalidomide Capsules from the U.S. Food and Drug Administration (USFDA)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Indian Study Shows Merck's COVID-19 Antiviral Candidate Less Effective Against Moderate Infection: Reuters ↗
According to a source with the Drug Controller General of India, Merck & Co Inc's (NYSE: MRK) antiviral drug molnupiravir has not shown "significant... 
Via Benzinga
News headline image
A Bit Of A Recovery ↗
While Germany remains without a government, Japan has a new prime minister who will lead his party in the election this week. 
Via Talk Markets
News headline image
Why This Citius Analyst Thinks The Biopharma's Shares Present 375% Upside Potential ↗
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) 
Via Benzinga
News headline image
Dr Reddy's To Sell Its Anti-Cancer Agent To Citius Pharma ↗
Citius Pharmaceuticals Inc has agreed to acquire anti-cancer agent E7777 from Dr. Reddy's Laboratories Ltd (NYSE: RDY). E7777 is an engineered IL-2-... 
Via Benzinga
News headline image
Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Mu - The Newest Worry ↗
Today London and New York fell on the huge drop in new employment levels in August. 
Via Talk Markets
News headline image
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories Announces the Launch of Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Delta Outbreak ↗
The US market was droopy because of poor private sector jobless numbers. 
Via Talk Markets
News headline image
BioDelivery Sciences Reports Mixed Q2 Earnings, Sees FY21 Belbuca Sales At Lower End Of Guidance Range ↗
BioDelivery Sciences International Inc (NASDAQ: BDSI) has reported Q2 sales of $41.4 million, + 13.3% Y/Y, missing the consensus of $42.4 million. Sales growth... 
Via Benzinga
News headline image
Dr. Reddy’s Laboratories Announces Entry Into Definitive Agreement with BioDelivery Sciences International, Inc., to Sell its U.S. and Canada Territory Rights for ELYXYB (celecoxib oral solution) 25 mg/mL
From Dr. Reddy’s Laboratories Limited
Via Business Wire
News headline image
Dr. Reddy’s Announces the Re-Launch of Over-the-Counter Naproxen Sodium Tablets USP, 220 mg, Store-Brand Equivalent of Aleve® in the U.S. Market
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.